$DTIL News

Last published 1w ago

1w agoDTILPRECISION BIOSCIENCES INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoDTILPrecision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
1mo agoDTILPrecision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
2mo agoDTILApproval of Alendronate Sodium, Anda #214523FDA Approved DrugsApproval Date: 09/02/2026; Drug Name: Alendronate Sodium, Anda #214523; Active Ingredients: ALENDRONATE SODIUM; Company: Precision Dose Inc; Submission Status: Approval; Application Number: 214523
2mo agoDTILiECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026Business WirePhase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events
2mo agoDTILPrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD StudyBusiness Wire-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – -First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care
2mo agoDTILiECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual SymposiumBusiness WireiECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing
3mo agoDTIL TGTXPrecision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - - In late-breaking data at EASL,
3mo agoDTILPrecision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
3mo agoDTILPrecision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical MilestonesBusiness Wire– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene
4mo agoDTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
4mo agoDTILPrecision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional InvestorsBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
5mo agoDTILJefferies Global Healthcare Conference in New York - PRECISION BIOSCIENCES INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the Precision Biosciences team. Maybe if you guys want to give an intro and a brief intro to the company as w
5mo agoDTILPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026Business Wire- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the <1% of cccDNA remaining,
5mo agoDTILPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026Business Wire- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - - Webcast will be held May 27th, 2026, at 8:00 AM EDT - Precision BioSciences,
5mo agoDTILiECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE TrialBusiness WireFirst infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following
6mo agoDTILPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual MeetingBusiness Wire– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – –
6mo agoDTILiECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual MeetingBusiness WirePreliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data
6mo agoDTIL TGTXPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver
6mo agoDTILPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
6mo agoDTILPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD StudyBusiness Wire- Arkansas Children's Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing
6mo agoDTILiECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual MeetingsBusiness WireiECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that clinical data from the
6mo agoDTILPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
6mo agoDTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
6mo agoDTILPrecision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026Business Wire- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B - Precision BioSciences, Inc.
7mo agoDTILPrecision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European CountriesBusiness Wire- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel
7mo agoDTILPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare ConferenceBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
7mo agoDTILiECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA SubmissionBusiness WireFDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical development timelines ECUR-506 selected as one of
8mo agoDTIL TGTXPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdateBusiness Wire- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - - Strong Phase 1 ELIMINATE-B trial execution
8mo agoDTILPrecision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV ProgramBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
8mo agoDTILPrecision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026Business Wire– Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment in a humanized DMD mouse model demonstrates
8mo agoDTILPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
8mo agoDTILPrecision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor EventBusiness Wire– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar to feature
8mo agoDTIL TGTXPrecision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple SclerosisBusiness Wire– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing
8mo agoDTILPrecision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific ConferenceBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
9mo agoDTILPrecision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular DystrophyBusiness Wire– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – Institutional Review
10mo agoDTILiECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyBusiness WireReached alignment with FDA on endpoints, comparators and sample size for the ongoing OTC-HOPE study which could support Biologics License Application (BLA) Awarded Innovation Passport under the United Kingdom's
10mo agoDTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today
11mo agoDTILPrecision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
1y agoDTILPrecision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and WarrantsBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,
1y agoDTILPrecision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three CohortsBusiness WirePBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at
1y agoDTILPrecision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire- Late-breaking oral presentation at the Liver Meeting® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B - Commenced dosing in Cohort 3 of the
1y agoDTILPrecision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
1y agoDTILPrecision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025Business WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
1y agoDTILPrecision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS NucleasesBusiness Wire- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and replacement of large
1y agoDTILPrecision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B TrialBusiness Wire- Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites - - Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing
1y agoDTILiECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual MeetingBusiness WireiECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that
1y agoDTILPrecision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle SocietyBusiness Wire- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end of 2025; clinical
1y agoDTILPrecision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
1y agoDTILPrecision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure SymposiumBusiness WirePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today